What does ARQ-234 program costs — R&D mean?

This metric represents the direct research and development expenditures specifically allocated to the advancement of the ARQ-234 clinical program. It captures the costs associated with preclinical studies, clinical trial execution, and regulatory development activities for this specific therapeutic candidate. Tracking these costs allows investors to assess the capital intensity and progress of the company's pipeline assets as they move through the drug development lifecycle.

Arcutis Biotherapeutics, Inc. (ARQT) ARQ-234 program costs — R&D

Screener

Other product segments

Topical roflumilast program costs

$1.98M-29.9%

Other program costs

$95K—

Similar metrics at other companies

AQSTPersonnel costs — R&D

$2.24M+5.2%

BMRNLater-stage clinical programs — R&D

$50.3M+283%

ABSIDrug creation program and platform — R&D

$6.08M+52.4%

INSMARIKAYCE external R&D expenses — R&D

$6.23M-43.4%

INSMBrensocatib external R&D expenses — R&D

$13.83M-58.8%

INSMTPIP external R&D expenses — R&D

$38.94M+88.6%

Other financials

Income statement

See full

Revenue$129.9M+59.3%

Gross profit$118.9M+60.7%

Operating income$16.4M+212%

Net income$15.0M+194%

EPS (diluted)$0.11+185%

Balance sheet

See full

Cash & equivalents$34.4M-52.9%

Total debt$114.1M+3.6%

Total equity$220.6M+58.7%

Total assets$488.5M+38.6%

Cash flow

See full

Operating cash flow$12.6M—

CapEx$158.0K+103%

Free cash flow$12.5M—

Valuation

See full

Market cap$3.32B+81.4%

Enterprise value$3.4B+82.1%

P/S7.2×+0.2×

Profitability

See full

Gross margin91.1%+2.0pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Returns & leverage

See full

Return on equity-28.2%-13.0pp

Debt / equity0.5×-0.3×

Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 4:21 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001787306-26-000051

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Less:
Cost of sales	10,376	6,929	19,598	12,780
Topical roflumilast program costs	1,983	2,827	5,290	4,273
ARQ-234 program costs	1,302	845	12,305	2,034
Other program costs	102	1,193	197	2,375
Research and development compensation and personnel-related expenses	11,366	9,779	22,411	19,417
Selling, general and administrative expenses	82,008	69,033	155,962	132,917
Other segment expenses(1)	6,295	5,509	12,156	12,694

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s ARQ-234 program costs — R&D?: Arcutis Biotherapeutics, Inc. (ARQT) reported ARQ-234 program costs — R&D of $1.3M in Q2 2026.
What does ARQ-234 program costs — R&D mean?: This metric represents the direct research and development expenditures specifically allocated to the advancement of the ARQ-234 clinical program. It captures the costs associated with preclinical studies, clinical trial execution, and regulatory development activities for this specific therapeutic candidate. Tracking these costs allows investors to assess the capital intensity and progress of the company's pipeline assets as they move through the drug development lifecycle.